BR112022014487A2 - Anticorpo bispecífico anti-pd-l1/vegf e usos do mesmo - Google Patents
Anticorpo bispecífico anti-pd-l1/vegf e usos do mesmoInfo
- Publication number
- BR112022014487A2 BR112022014487A2 BR112022014487A BR112022014487A BR112022014487A2 BR 112022014487 A2 BR112022014487 A2 BR 112022014487A2 BR 112022014487 A BR112022014487 A BR 112022014487A BR 112022014487 A BR112022014487 A BR 112022014487A BR 112022014487 A2 BR112022014487 A2 BR 112022014487A2
- Authority
- BR
- Brazil
- Prior art keywords
- bispecific anti
- antibody
- vegf antibody
- bispecific
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020073497 | 2020-01-21 | ||
| PCT/CN2021/072584 WO2021147829A1 (en) | 2020-01-21 | 2021-01-19 | A bispecific anti-pd-l1/vegf antibody and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014487A2 true BR112022014487A2 (pt) | 2022-09-27 |
Family
ID=76993149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014487A BR112022014487A2 (pt) | 2020-01-21 | 2021-01-19 | Anticorpo bispecífico anti-pd-l1/vegf e usos do mesmo |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230242645A1 (https=) |
| EP (1) | EP4093765A4 (https=) |
| JP (1) | JP7692422B2 (https=) |
| AU (1) | AU2021210025A1 (https=) |
| BR (1) | BR112022014487A2 (https=) |
| CA (1) | CA3165556A1 (https=) |
| WO (1) | WO2021147829A1 (https=) |
| ZA (1) | ZA202208337B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114106190B (zh) * | 2020-08-31 | 2025-04-08 | 普米斯生物技术(珠海)有限公司 | 一种抗vegf/pd-l1双特异性抗体及其用途 |
| CN114230669B (zh) * | 2021-12-24 | 2024-01-30 | 天士力生物医药股份有限公司 | 一种双特异性抗体的生产方法 |
| EP4543488A2 (en) * | 2022-08-25 | 2025-04-30 | Bright Biologics LLC | Multispecific antibodies and uses thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025257394A1 (en) * | 2024-06-14 | 2025-12-18 | BioNTech SE | Combination therapy for cancer treatment |
| WO2025256761A1 (en) * | 2024-06-14 | 2025-12-18 | BioNTech SE | Combination therapy for cancer treatment |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| CN109575140B (zh) * | 2017-09-29 | 2021-02-23 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
| CA3090878A1 (en) * | 2018-02-11 | 2019-08-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-pd-1/anti-vegf natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof |
| EP3758735B1 (en) * | 2018-02-28 | 2023-12-13 | AP Biosciences, Inc. | Bifunctional proteins combining checkpoint blockade for targeted therapy |
| CN110305210B (zh) * | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| WO2019184909A1 (zh) * | 2018-03-27 | 2019-10-03 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| CN109942712B (zh) * | 2019-04-01 | 2022-12-20 | 华博生物医药技术（上海）有限公司 | 抗pd-l1/vegf双功能抗体及其用途 |
| WO2021057836A1 (en) | 2019-09-25 | 2021-04-01 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
-
2021
- 2021-01-19 EP EP21744356.3A patent/EP4093765A4/en active Pending
- 2021-01-19 WO PCT/CN2021/072584 patent/WO2021147829A1/en not_active Ceased
- 2021-01-19 AU AU2021210025A patent/AU2021210025A1/en active Pending
- 2021-01-19 JP JP2022544267A patent/JP7692422B2/ja active Active
- 2021-01-19 BR BR112022014487A patent/BR112022014487A2/pt unknown
- 2021-01-19 CA CA3165556A patent/CA3165556A1/en active Pending
- 2021-01-19 US US17/792,386 patent/US20230242645A1/en active Pending
-
2022
- 2022-07-26 ZA ZA2022/08337A patent/ZA202208337B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021210025A1 (en) | 2022-08-25 |
| WO2021147829A1 (en) | 2021-07-29 |
| CA3165556A1 (en) | 2021-07-29 |
| US20230242645A1 (en) | 2023-08-03 |
| JP2023511898A (ja) | 2023-03-23 |
| ZA202208337B (en) | 2024-01-31 |
| EP4093765A1 (en) | 2022-11-30 |
| JP7692422B2 (ja) | 2025-06-13 |
| EP4093765A4 (en) | 2023-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014487A2 (pt) | Anticorpo bispecífico anti-pd-l1/vegf e usos do mesmo | |
| MX2024000317A (es) | Anticuerpos biespecificos contra calicreina y factor xii del plasma. | |
| ECSP19010852A (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso | |
| AR111418A1 (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| EA201990285A1 (ru) | Гетеродимерные иммуноглобулиновые конструкции и способы их получения | |
| BR112022022800A2 (pt) | Métodos para tratamento de mieloma múltiplo | |
| EA201990894A1 (ru) | Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения | |
| EA201691225A1 (ru) | Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение | |
| NZ611269A (en) | Neutralizing anti-ccl20 antibodies | |
| JOP20210286A1 (ar) | جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr | |
| NZ778430A (en) | Monoclonal antibodies that bind specifically to human trbv9 | |
| UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
| WO2016112078A3 (en) | Anti-phf-tau antibodies and their uses | |
| BR112022020742A2 (pt) | Anticorpo anti-ox40 e usos do mesmo | |
| IL285308A (en) | Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met | |
| MX2022002672A (es) | Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo. | |
| BR112021016596A2 (pt) | Anticorpo anti-pd-l1 e uso do mesmo | |
| MX2024014232A (es) | Anticuerpo anti-b7h3 y usos del mismo | |
| BR112022021077A2 (pt) | Anticorpos humanizados antifator bb de complemento e uso dos mesmos | |
| BR112018076247A2 (pt) | anticorpos monoclonais quiméricos e humanizados para cd81 | |
| EA202190698A1 (ru) | Гуманизированные анти-c5 антитела и их применение | |
| ZA202106551B (en) | Anti-bag2 antibody and methods of treating cancer | |
| EA202091738A1 (ru) | Способы лечения рака антителами-антагонистами к pd-1 | |
| EA202092743A1 (ru) | Антитела к il36r | |
| AR113452A1 (es) | Anticuerpos anti-tau y sus usos |